Hosted on MSN9h
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
Pharmabiz17h
EMA committee recommends marketing approval for AbbVie’s mirvetuximab soravtansine for the treatment of certain adult ovarian cancer
North Chicago, Illinois Monday, September 23, 2024, 13:00 Hrs [IST] ...
Medscape3d
EMA Backs Approval of Elahere for Ovarian Cancer
Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...
The American Journal of Managed Care8d
Dr Angeles Alvarez Secord on "Exciting" Responses With Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer
Mirvetuximab soravtansine showed high evidence of efficacy in heavily pretreated FRα-positive, platinum-sensitive ovarian ...
Targeted Oncology9h
Peers Discuss Molecular Testing and Time of Recurrence in Endometrial Cancer
During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...
AbbVie: CHMP Adopts Positive Opinion For Mirvetuximab Soravtansine - Quick Facts
AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...
Hosted on MSN6mon
Elahere secures full approval from FDA for types of ovarian cancer
AbbVie’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) has bagged full approval from the US Food and Drug Administration (FDA) for the treatment of certain types of ovarian cancer.
Medscape3d
Conjugated Antibodies: Emerging Star in Ovarian Cancer Tx
Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...
The Pharma Letter3d
Latest batch of EMA’s human medicines committee recommendations
Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket
The surge in global cancer cases is raising serious concerns among experts. A recent study published in Monday in Cancer, a ...
Abbvie Slides on ELAHERE Opinion of its Cancer Treatment
AbbVie (NYSE: ABBV) shares lost ground Friday. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...